The loss of exclusivity of semaglutide is one of the most significant recent pharmaceutical market events that has happened in Canada. This drug class has transformed the treatment of type 2 diabetes and obesity in recent years -- and is now entering a pivotal new chapter.

As the Canadian market opens up to generic competition for semaglutide, stakeholders across the healthcare ecosystem are closely watching how increased competition may influence pricing, access, distribution, reimbursement, prescribing patterns, and patient uptake. Canada is among the first major markets globally to experience semaglutide going off patent, making it an important indicator of how the off-patent semaglutide market may evolve.

New entrants, evolving payer policies, manufacturer response strategies, and changing patient pathways are creating a dynamic environment that will continue to develop over the coming months and years. This page provides a central location where we will offer ongoing updates, insights, and analysis on the genericization of semaglutide in Canada.

Using IQVIA's unparalleled data, we’ll provide the latest on generic uptake, market dynamics, competitor activity, reimbursement developments, and emerging opportunities as the post-exclusivity market continues to take shape.